SCHEMBL4515375

SCHEMBL4515375

COc1ccc(Cl)cc1NS(=O)(=O)c1ccc(OC)c2c1OC[C@H](NC(=O)C(F)(F)F)C2

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.49
QRFPR Q96P65 1/20 0.49
POLB P06746 2/20 0.45
MAPT P10636 2/20 0.45
WDR5 P61964 3/20 0.42
ALDH1A1 P00352 4/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 2/20 0.41
LMNA P02545 2/20 0.41
NPC1 O15118 1/20 0.41
TSHR P16473 1/20 0.41
PTGDR Q13258 2/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MYC P01106 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522968 0.90 IDH1 (0.40) HTR6POLBMAPTALDH1A1TP53
SCHEMBL4529640 0.89 TP53 (0.44) HTR6QRFPRPOLBMAPTTP53
SCHEMBL4961539 0.86 THRB (0.48) MAPTALDH1A1LMNATSHRMEN1
SCHEMBL4505898 0.85 MALT1 (0.41) HTR6MAPTALDH1A1LMNATSHR
SCHEMBL4505107 0.84 HTR6 (0.64) HTR6QRFPRWDR5ALDH1A1TP53
SCHEMBL4512345 0.84 FABP4 (0.41) MAPTALDH1A1LMNATSHRMEN1
SCHEMBL4521563 0.83 MTNR1A (0.36) POLBMAPTLMNAHTT
SCHEMBL4523963 0.82 MEN1 (0.44) MAPTALDH1A1MAPK1PTGDRPTGDR2
SCHEMBL4527771 0.81 MAPT (0.46) POLBMAPTTP53MAPK1LMNA
SCHEMBL4522539 0.81 HTR6 (0.56) HTR6QRFPRPOLBMAPTWDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
EP-1888518-A1 NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126938-A1 NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor HTR6, HTR1D, HTR1A HTR6 1/4885QRFPR 79/4885POLB 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.